<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container" style="height:100vh;"><div class="content-main"> <div class="answer_container" style="min-height:100%;" data-v-61fabe50=""><div class="content_outer_container" data-v-61fabe50=""><div class="share_preview_container" data-v-61fabe50=""><div class="dialog_list" data-v-61fabe50=""><div class="dialog_item" data-v-61fabe50=""><div class="dialog_question fir_dialog_question" data-v-61fabe50=""><div class="question_con" data-v-61fabe50=""><h1 class="fir_question_content" data-v-61fabe50="">
                                    lly
                                </h1> <div class="user_slot" data-v-61fabe50=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-61fabe50=""> <span class="user_desction" data-v-61fabe50="">
                                        
                                        7/1/2025 10:10pm
                                    </span></div></div></div> <div class="seo-text-answer" data-v-61fabe50="">**Eli Lilly and Company (LLY)展现强劲的增长潜力**，在肥胖治疗领域的地位日益突出，推动股价接近目标价。以下是支持这一结论的关键点：

1. **乐观的市场前景**：Citi对Eli Lilly的肥胖治疗管线持乐观态度，预计到2030年该领域销售额将达到400亿美元，远高于共识估计的250亿美元。Mounjaro在印度的推出被视为对诺和诺德的有力竞争，分析师预计未来一年内股价有22.14%的上涨潜力。
2. **强劲的财务表现**：Eli Lilly表现出强大的收入增长28%的年化收益率，拥有令人瞩目的42%的股本</div> <div class="dialog_answer" data-v-61fabe50=""><div class="dialog_content" data-v-61fabe50=""><div class="answer_content" data-v-61fabe50=""></div></div></div></div></div> </div></div></div></div> </div> <div class="extra-module" style="height:100vh;" data-v-4ca41778=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-4ca41778=""> <div class="recommend-part" data-v-7790c618="" data-v-4ca41778=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae){ad[0]={event_name:w,event_type:D,content:{}};return {layout:"default",data:[{noData:d,currentQuestion:e,textDescription:C,comeFrom:"AInvestShareLink",events:[{event_name:w,event_type:D,content:{}}],answerSource:p}],fetch:{},error:g,state:{sharePreviewModule:{loadJgySuccess:E,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:1,agent_id:a,output_media_info:[],task_id:a,language:a,source:p,cache_builder:a,reply_action:"Answer",execute_mode:F,event_refresh_answer:a,param:"{\"entity_info\":{\"comefrom\":\"WebaimeRobot\",\"device_type\":\"browser\",\"logged_in\":\"1\"},\"add_info\":{\"urp\":{\"component_version\":\"1.1.3\",\"user\":\"MDpsaDE3NDk3NDY1NDI0MzQ6Ok5vbmU6NTAwOjE4MTUzMzE5NTQ6Ojo6OjE4MDUzMzE5NTQ6MTc0OTc0NjU0Mjo6OjE3NDk3NDQ0MDU6MjY3ODQwMDowOjEzMDNkYWRhY2U3MjU4YzVhOWYzYTNlZGMzNTc0NTc5Mjo6MA==\",\"ticket\":\"ca333319b25203923067681694a336b1\",\"realtime_hkdata\":\"0\"},\"ori_question\":\"lly\"},\"event_list\":[{\"event_name\":\"auto_agent\",\"event_type\":\"user_input\",\"content\":{}}],\"client_ip\":\"71.236.37.117\",\"question\":\"lly\",\"user_id\":\"1805331954\",\"user_name\":\"\",\"trace_id\":\"20003020175137901211000000000066\",\"session_id\":\"bb9f8da0b860f81170b5a05dff624a76\",\"source\":\"ths_wencai_international_pc_robot\",\"input_type\":\"click\"}",agent_info:[{info_type:G,raw_data:{number:H,title:I,summary:J,full_summary:a,url:K,image_url:a,video_url:a,publish_time:L,search_extra_info:{search_burial_info:{id:l,uid:l,ab:{scene_id:q,layer_exp:[{layer_id:r,exp_id:s}]}}},simhash:"afbad4417c6dc1ff",msg_id:l}},{info_type:G,raw_data:{number:M,title:N,summary:O,full_summary:a,url:P,image_url:a,video_url:a,publish_time:Q,search_extra_info:{search_burial_info:{id:m,uid:m,ab:{scene_id:q,layer_exp:[{layer_id:r,exp_id:s}]}}},simhash:"ef8eaafc3db3c45b",msg_id:m}}],answer_chain_name:"agent_common_v2\nagent-summary",agent_mode:R,native_answer:a,come_from:S,text_answer:C,trace_id:x,cost:10625,event_names:w,question:e,fallback_type:T,input_type:U,fall_back_reason:{fall_back_type:T,may_fall_back_reason:"UNKNOWN",risk_detail:{matched_words:[]}},session_id:y,first_return_cost:3134,cache_type:"no_cache",question_id:"5f077aca-96e0-4893-9c78-242366f1a3f5",transfer_question:e,signal_type:"CANCEL",start_time:z,remote_svc:"aime-gateway",slots:[],answer_type:F,user_id:t,skill_name:V},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:x,session_id:y,user_id:t,question:e,source:p,raw_question:e,version:"3.4.1",action_name:V,nlu:{entity:[{name:A,type:W,value:"LLY.N",market:X}]},output_time:z,deep_research:d,deep_thinking:d,agent_mode:R},extra:{}},{answer_path:h,section:{id:i,info_texts:["Thinking"],show_type:j,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},logs:[],extra:{is_deep_research:d,deep_thinking:d}},{answer_path:c,section:{id:n,info_texts:[],show_type:o,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:h,section:{id:i,info_texts:["Querying Stock: LLY Closing Price, Resistance Level, Support Level"],show_type:j,choice:[],result_page:{},tag_info_list:[],is_last:b,status:u},logs:[],extra:{action:B,action_input:"LLY Closing Price, Resistance Level, Support Level",thought:v}},{answer_path:h,section:{id:i,info_texts:["Querying Stock: LLY P\u002FE Ratio, P\u002FB Ratio, P\u002FS Ratio"],show_type:j,choice:[],result_page:{},tag_info_list:[],is_last:b,status:u},logs:[],extra:{action:B,action_input:"LLY P\u002FE Ratio, P\u002FB Ratio, P\u002FS Ratio",thought:v}},{answer_path:h,section:{id:i,info_texts:["Querying Stock: LLY Dividend Yield, Dividend Continuous Duration, Dividend Growth Duration"],show_type:j,choice:[],result_page:{},tag_info_list:[],is_last:b,status:u},logs:[],extra:{action:B,action_input:"LLY Dividend Yield, Dividend Continuous Duration, Dividend Growth Duration",thought:v}},{answer_path:h,section:{id:i,info_texts:["Searching Web: Eli Lilly recent analysis"],show_type:j,choice:[],result_page:{},tag_info_list:[],is_last:b,status:u},logs:[],extra:{action:"Searching Web",action_input:"Eli Lilly recent analysis",thought:v}},{answer_path:c,section:{id:n,info_texts:[],show_type:o,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:c,section:{id:n,info_texts:[],show_type:o,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:c,section:{id:n,info_texts:[],show_type:o,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:h,section:{id:i,info_texts:["Generating Answer"],show_type:j,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},logs:[],extra:{reasoning_cost:6851}},{answer_path:c,section:{id:k,info_texts:[],show_type:f,voice_txt:"**",text_answer:Y,rich_text:Y,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:c,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:"LLY",market_id:X,name:A,domain:W},pos:2,section_id:k,txt:A,jump_type:"pos_fenshi"}],is_last:b},logs:[],extra:{}},{answer_path:c,section:{id:k,info_texts:[],show_type:f,voice_txt:"C",text_answer:Z,rich_text:Z,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:c,section:{id:_,info_texts:[],show_type:f,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{url:K,image_url:a,video_url:a,title:I,summary:J,index:H,publish_time:L,search_id:l,search_uid:l,search_ab:{scene_id:q,layer_exp:[{layer_id:r,exp_id:s}]},jump_type:$}],is_last:b},logs:[],extra:{}},{answer_path:c,section:{id:k,info_texts:[],show_type:f,voice_txt:"。",text_answer:aa,rich_text:aa,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:c,section:{id:_,info_texts:[],show_type:f,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{url:P,image_url:a,video_url:a,title:N,summary:O,index:M,publish_time:Q,search_id:m,search_uid:m,search_ab:{scene_id:q,layer_exp:[{layer_id:r,exp_id:s}]},jump_type:$}],is_last:b},logs:[],extra:{}},{answer_path:c,section:{id:k,info_texts:[],show_type:f,voice_txt:"。\n",text_answer:ab,rich_text:ab,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:c,section:{id:n,info_texts:[],show_type:o,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:c,section:{id:k,info_texts:[],show_type:f,voice_txt:"化",text_answer:ac,rich_text:ac,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}}],questionItem:{data:{qStr:e,encodeFlag:d,imageData:g,docsData:g,quoteData:g},tplType:"question"},events:ad,agentId:a,param:{entity_info:{comefrom:S,device_type:"browser",logged_in:"1"},add_info:{urp:{component_version:"1.1.3",user:"MDpsaDE3NDk3NDY1NDI0MzQ6Ok5vbmU6NTAwOjE4MTUzMzE5NTQ6Ojo6OjE4MDUzMzE5NTQ6MTc0OTc0NjU0Mjo6OjE3NDk3NDQ0MDU6MjY3ODQwMDowOjEzMDNkYWRhY2U3MjU4YzVhOWYzYTNlZGMzNTc0NTc5Mjo6MA==",ticket:"ca333319b25203923067681694a336b1",realtime_hkdata:"0"},ori_question:e},event_list:ad,client_ip:"71.236.37.117",question:e,user_id:t,user_name:a,trace_id:x,session_id:y,source:p,input_type:U}}],userId:t,userName:a,startTime:z,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:g,endSignal:d,theme:"white",showTracePopup:d,traceListData:[],chatTraceTargetIndex:E,traceTableData:g,showMask:d}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Flly-b8be62\u002F",config:{_app:{basePath:ae,assetsPath:ae,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,"other\u002FopenAnswer",false,"lly","rich_text",null,"progress\u002Fsearching_for",1000,"searching_for",2001,"d5a3aeedada39c79","882dc24630835e3e",999,"signal","ths_wencai_international_pc_robot","oeqxkhszf","oeqxkhszf_layer","base","1805331954","thinking","The user seeks information on LLY. I should focus on its stock price, valuation, dividend payments, and relevant market analysis. I will use FinQuery for the data mentioned above; use Search for the related market analysis.","auto_agent","20003020175137901211000000000066","bb9f8da0b860f81170b5a05dff624a76",1751379012124,"Eli Lilly","Querying Stock","**Eli Lilly and Company (LLY)展现强劲的增长潜力**，在肥胖治疗领域的地位日益突出，推动股价接近目标价。以下是支持这一结论的关键点：\n\n1. **乐观的市场前景**：Citi对Eli Lilly的肥胖治疗管线持乐观态度，预计到2030年该领域销售额将达到400亿美元，远高于共识估计的250亿美元。Mounjaro在印度的推出被视为对诺和诺德的有力竞争，分析师预计未来一年内股价有22.14%的上涨潜力。\n2. **强劲的财务表现**：Eli Lilly表现出强大的收入增长28%的年化收益率，拥有令人瞩目的42%的股本","user_input",0,"agent","search",4,"Citi Expresses Optimism for Eli Lilly and Company (LLY)","Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Long Term Growth Stocks to Invest in Right Now. On June 25, Citi reported that “compelling” data shows that Eli Lilly and Company (NYSE:LLY) and Novo Nordisk (NVO) have turned obesity into a treatable disease from a lifestyle-based condition. The firm models more than $40 billion in obesity sales by 2030, well above the consensus estimates of $25 billion. Citi stated that as the obesity space evolves from injectables to convenient orals, such as orforglipron, the emergence of a “dynamic” consumer-centric market is possible, and LillyDirect by Eli Lilly and Company (NYSE:LLY) is well-positioned to connect high consumer visibility for orforglipron with global access. In a research note, Citi further stated that it estimated penetration rates via income-based tiers for pricing and out-of-pocket costs in low- and mid-body mass index patients. The results place Eli Lilly and Company’s (NYSE:LLY) consumer platform opportunity at $15B, which is not assumed in the firm’s model. It thus believes that Eli Lilly and Company’s (NYSE:LLY) is in a position to expedite access outside the US, employing a centralized out-of-pocket payment model instead of the traditional country-by-country launch. It contended that an “income-based tiered pricing of orforglipron via LillyDirect could unlock unprecedented volume, all the while allowing it to maintain overall pricing power.” Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies. Investors are bullish on Eli Lilly and Company (NYSE:LLY) due to its in-demand GLP-1 drugs, used to treat diabetes and obesity, which are still in their early growth stages, and the company’s strong financials. ","https:\u002F\u002Ffinance.yahoo.com\u002Fnews\u002Fciti-expresses-optimism-eli-lilly-085259157.html","2025-06-28",5,"Eli Lilly (LLY) Expands Mounjaro in India, Competing with Novo Nordisk","Eli Lilly's (LLY, Financial) new launch of Mounjaro in India challenges Novo Nordisk's market stronghold. Analysts see a significant potential upside in the stock price. GuruFocus estimates suggest substantial growth for Eli Lilly within the next year. Eli Lilly (NYSE: LLY) is making waves in the global weight-loss drug market with its recent approval from India's drug regulator to launch Mounjaro pre-filled injector pens. This strategic move positions Eli Lilly as a formidable competitor to Novo Nordisk's popular Wegovy. Wall Street Analysts' Forecast Analyst projections offer a compelling outlook for Eli Lilly, with 26 analysts setting a one-year price target that averages $967.71. The forecasts range from a high of $1,190.00 to a low of $675.00, indicating an upside potential of 22.14% from its current trading price of $792.30. For a more comprehensive analysis, please visit the Eli Lilly and Co (LLY, Financial) Forecast page. The consensus among 29 brokerage firms gives Eli Lilly an average recommendation rating of 2.0, which suggests the stock is currently in \"Outperform\" territory. This rating scale, ranging from 1 to 5, provides investors with a clear indication of the stock's potential, with 1 representing a Strong Buy and 5 indicating a Sell. GuruFocus GF Value Estimation According to GuruFocus estimates, Eli Lilly's GF Value in the next year is projected at $1199.00. ","https:\u002F\u002Fwww.gurufocus.com\u002Fnews\u002F2947101\u002Feli-lilly-lly-expands-mounjaro-in-india-competing-with-novo-nordisk","2025-06-26","normal_agent","WebaimeRobot","NONE","click","review stocks","stock","169","**Eli Lilly and Company (LLY)展现强劲的增长潜力**，在肥胖治疗领域的地位日益突出，推动股价接近目标价。以下是支持这一结论的关键点：\n\n1. **乐观的市场前景**：","Citi对Eli Lilly的肥胖治疗管线持乐观态度，预计到2030年该领域销售额将达到400亿美元，远高于共识估计的250亿美元[^4]",2000,"normal","。Mounjaro在印度的推出被视为对诺和诺德的有力竞争，分析师预计未来一年内股价有22.14%的上涨潜力[^5]","。\n2. **强劲的财务表现**：Eli Lilly表现出强大的收入增长28%的年","化收益率，拥有令人瞩目的42%的股本",Array(1),"\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/68c2f12.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/a3ef411.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/0dede14.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a2c4cd.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/31d66e9.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/0b8d5a5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/bea6536.js" defer=""></script>